Press Release: Source Biomagnetics Diagnostics Corporation

Biomagnetics to Hold Investor Conference Call to Introduce World Class Biosensor Technology for Malaria, HIV and Tuberculosis Diagnosis Tuesday Dec 01, 03:00 pm ET

SAN FRANCISCO--(BUSINESS WIRE)--Biomagnetics Diagnostics Corp. (PINK SHEETS:BMGP),a developer of revolutionary diagnostic systems and technology for HIV, hepatitis, tuberculosis and malaria detection, recently announced in November that the Company will hold an investor conference call to discuss upcoming business opportunities and its agreement with Los Alamos National Security, one of the world’s premiere research laboratories.

Specifically, the call, which will be open to all investors, will be held on Wednesday, December 2nd at 4:30 EST. Interested parties may dial into the Biomagnetics Diagnostics Corp. conference call using the toll free dial-in number (US & Canada) of (888) 858-6021 or the local toll dial-in number of (973) 935-2037. The conference pass code to access the call is 5913680359.

“It is a very exciting time for all of us at Biomagnetics as well as our shareholders. For the past few quarters, we have been working on several major growth initiatives that are now coming to fruition,” commented Clayton Hardman, CEO of Biomagnetics Diagnostics. “Please join us on tomorrow’s investor conference call as we discuss the pending introduction of our revolutionary technologies for malaria, HIV, tuberculosis and other pathogen and disease diagnosis and as we profile our new and evolving relationship with one of the world’s premiere research institutions, Los Alamos National Security. We view our current business opportunities as being highly significant.”

The Company recently announced on November 30th that it has finalized a "Patent License Agreement with Los Alamos National Security." Under the agreement, Biomagnetics will have access to the Triggered Optical Biosensor and Integrated Optical Biosensor System (IBOS) technology developed at Los Alamos National Laboratory.

According to the World Health Organization, some 3.2 billion people, or about half of the world's population is at risk of malaria transmission in 107 countries and territories worldwide. While there are between 350 million and 500 million new cases of malaria each year, there are very few reliable and field deployable diagnostic tools available. In the case of malaria, early detection substantially improves treatability and survivability. Field deployable Integrated Optical Biosensor System (IBOS), such as those Biomagnetics Diagnostics is planning to soon introduce, hold the promise to significantly speed the diagnostic testing process and to meaningfully lower costs and improve lives.

About BioMag Corporation

Biomag Corporation, through its wholly owned subsidiary, Biospectrum Technologies, Inc., a company that has designed and patented revolutionary diagnostic equipment and immunoassays, will identify market inadequacies and fill those needs with new technologies and highly specific and sensitive assays that are qualitative, (yes/no) and quantitative (viral load/degree of infection), easily performed and cost effective.

Contact: Biomagnetics Diagnostics, Corp
Joe Noel, 925-922-2560